{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:06:01Z","timestamp":1788285961457,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.iotech.2025.101077","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:26:52Z","timestamp":1760074012000},"page":"101077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2110-5712","authenticated-orcid":false,"given":"N.","family":"Alshatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-2378","authenticated-orcid":false,"given":"J.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Llamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Damotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Velut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mauduit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Charette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Palard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"A.","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iotech.2025.101077_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.iotech.2025.101077_bib2","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.iotech.2025.101077_bib3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.iotech.2025.101077_bib4","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.iotech.2025.101077_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: a case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.iotech.2025.101077_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1011484","article-title":"Kick-starting the cancer-immunity cycle by targeting CD40","volume":"4","author":"Ellmark","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.iotech.2025.101077_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.iotech.2025.101077_bib8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.iotech.2025.101077_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/10503","article-title":"Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40","volume":"5","author":"Sotomayor","year":"1999","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.iotech.2025.101077_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.iotech.2025.101077_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.iotech.2025.101077_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3892\/ol.2020.12037","article-title":"Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies","volume":"20","author":"Li","year":"2020","journal-title":"Oncol Lett"},{"issue":"11","key":"10.1016\/j.iotech.2025.101077_bib13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/intimm\/dxn104","article-title":"Deliberately provoking local inflammation drives tumors to become their own protective vaccine site","volume":"20","author":"Jackaman","year":"2008","journal-title":"Int Immunol"},{"issue":"8","key":"10.1016\/j.iotech.2025.101077_bib14","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-10-2888","article-title":"Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody","volume":"17","author":"Fransen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.iotech.2025.101077_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","article-title":"Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer","volume":"2","author":"Sandin","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.iotech.2025.101077_bib16","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.iotech.2025.101077_bib17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"issue":"1 Suppl","key":"10.1016\/j.iotech.2025.101077_bib18","first-page":"e641","article-title":"The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells","volume":"128","author":"Cycon","year":"2009","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.iotech.2025.101077_bib19","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"Tran Janco","year":"2015","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.iotech.2025.101077_bib20","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI119822","article-title":"CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy","volume":"100","author":"Schultze","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.iotech.2025.101077_bib21","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood-2003-07-2379","article-title":"RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy","volume":"103","author":"Coughlin","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iotech.2025.101077_bib22","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/10495","article-title":"CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy","volume":"5","author":"Diehl","year":"1999","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.iotech.2025.101077_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/8426","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French","year":"1999","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.iotech.2025.101077_bib24","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.168.6.2720","article-title":"T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody","volume":"168","author":"Tutt","year":"2002","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.iotech.2025.101077_bib25","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1182\/blood-2006-11-057216","article-title":"Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation","volume":"109","author":"French","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iotech.2025.101077_bib26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.iotech.2025.101077_bib27","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4049\/jimmunol.1303204","article-title":"Fc\u03b3 receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization","volume":"193","author":"White","year":"2014","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.iotech.2025.101077_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00281-006-0058-8","article-title":"Fc gamma receptors and cancer","volume":"28","author":"Cassard","year":"2006","journal-title":"Springer Semin Immunopathol"},{"issue":"3","key":"10.1016\/j.iotech.2025.101077_bib29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/2326-6066.CIR-14-0226","article-title":"Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment","volume":"3","author":"Zippelius","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.iotech.2025.101077_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"14","key":"10.1016\/j.iotech.2025.101077_bib31","doi-asserted-by":"crossref","first-page":"18508","DOI":"10.18632\/oncotarget.7610","article-title":"Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model","volume":"7","author":"Luheshi","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.iotech.2025.101077_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","article-title":"A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.iotech.2025.101077_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2022.05.001","article-title":"SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils","volume":"169","author":"Velut","year":"2022","journal-title":"Lung Cancer"},{"issue":"6-7","key":"10.1016\/j.iotech.2025.101077_bib34","first-page":"688","article-title":"[Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: principles and perspectives]","volume":"22","author":"Boulle","year":"2018","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.iotech.2025.101077_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940674","article-title":"Next generation CD40 agonistic antibodies for cancer immunotherapy","volume":"13","author":"Salomon","year":"2022","journal-title":"Front Immunol"},{"issue":"suppl 7","key":"10.1016\/j.iotech.2025.101077_bib36","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1538-7445.AM2023-5079","article-title":"Intratumoral CD40 agonist enhances the antitumor effect of anti-PD1 immunotherapy by activation of antigen-presenting cells and selective expansion of effector CD8+ T cells","volume":"83","author":"Pazdrak","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.iotech.2025.101077_bib37","article-title":"615 Intratumoral Fc-engineered agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in metastatic cancer patients. A bench-to-bedside and back approach","volume":"12","author":"Osorio","year":"2024","journal-title":"J ImmunoTherapy Cancer"},{"issue":"5","key":"10.1016\/j.iotech.2025.101077_bib38","first-page":"1539","article-title":"Experience in daily practice with ipilimumab for the treatment of metastatic melanoma: an early increase in FDG uptake in lymph nodes and spleen predicts response to therapy","volume":"48","author":"Delyon","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.iotech.2025.101077_bib39","article-title":"Phase I study of CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors","volume":"8","author":"Vonderheide","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018825000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018825000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:28:14Z","timestamp":1774484894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018825000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S2590018825000371"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2025.101077","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2025.101077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101077"}}